Nizatidine: Difference between revisions

| verifiedrevid = 408778819

| IUPAC_name = ''N''-(2-[(2-[(dimethylamino)methyl]thiazol-4-yl)methylthio]ethyl)-''N''-methyl-2-nitroethene-1,1-diamine

| image = Nizatidine structure.png

| tradename = Axid

| licence_US = Nizatidine

| routes_of_administration = Oral

| metabolism = [[Liver|Hepatic]]

| elimination_half-life = 1-2 hours

| excretion = [[Kidney|Renal]]

| CASNo_Ref = {{cascite|correct|CAS}}

| ATC_prefix = A02

| ATC_suffix = BA04

| ATC_supplemental =

| C=12 | H=21 | N=5 | O=2 | S=2

| molecular_weight = 331.46 g/mol

| InChI = 1/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+

| InChIKey = SGXXNSQHWDMGGP-IZZDOVSWBC

'''Nizatidine''' is a histamine [[H2-receptor antagonist|H₂-receptor antagonist]] that inhibits [[gastric acid|stomach acid]] production, and commonly used in the treatment of [[peptic ulcer]] disease (PUD) and [[gastroesophageal reflux]] disease (GERD). It was developed by [[Eli Lilly and Company|Eli Lilly]] and is marketed under the brand names '''Tazac''' and '''Axid'''.

==Clinical use==

{{main|H2-receptor antagonist}}

Certain preparations of nizatidine are now available [[Over-the-counter drug|over the counter]] in various countries including the United States. Nizatidine has been used experimentally to control weight gain associated with some antipsychotic medication. <ref name="pmid14716710">{{cite journal

|author=Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N

|title=Nizatidine for the treatment of patients with quetiapine-induced weight gain

|journal=Hum Psychopharmacol

|volume=19

|issue=1

|pages=37–40

|year=2004

|month=January

|pmid=14716710

|doi=10.1002/hup.477

}}</ref>

Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]]-ring in place of the [[furan]]-ring in ranitidine. In September 2000 Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]]. <ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 Eli Lilly and Company and Reliant Pharmaceuticals Announce<!-- Bot generated title -->]</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). <ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref> However, a year later they sold rights of the Axid Oral Solution (including the issued patent [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 US6,930,119] protecting the product) to [[Braintree Laboratories]].<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref>

Nizatidine proved to be the last new histamine H₂-receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.

==References==

{{Reflist|2}}

==External links==

* http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2929

* [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=AXID Axid @ FDA]

* [http://www.axidos.com/ Axid Oral Solution]

{{Histaminergics}}

[[Category:Eli Lilly and Company]]

[[Category:Nitroethenes]]

[[es:Nizatidina]]

[[it:Nizatidina]]

[[ja:ニザチジン]]

[[nl:Nizatidine]]

[[th:นิซาทิดีน]]